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OBJECTIVE
We examined the association of lactation duration with incident type 2 diabetes
among women with a history of gestational diabetes mellitus (GDM).
RESEARCH DESIGN AND METHODS
We monitored 4,372 women with a history of GDM participating in the Nurses’
HealthStudy II for incident type2diabetesover25yearsupto2017. Lactationhistory
was obtained through follow-up questionnaires to calculate lactation duration.
Follow-up blood samples were collected from a subset of thesewomen atmedian
age of 58 years through the Diabetes & Women’s Health Study.
RESULTS
Wedocumented873 incident cases of type2diabetes during 87,411 person-years
of follow-up. Longer duration of lactationwas associatedwith lower risk of type 2
diabetes for both total lactation (hazard ratio 1.05 [95% CI 0.83–1.34] for up to
6 months, 0.91 [0.72–1.16] for 6–12 months, 0.85 [0.67–1.06] for 12–24 months,
and 0.73 [0.57–0.93] for >24months, compared with 0months; P-trend5 0.003)
and exclusive breastfeeding (P-trend5 0.002) after adjustment for age, ethnicity,
family history of diabetes, parity, age at first birth, smoking, diet quality, physical
activity, and prepregnancy BMI. Longer duration of lactation was also associated
with lower HbA1c, fasting plasma insulin, and C-peptide concentrations among
women without type 2 diabetes at follow-up (all adjusted P-trend £0.04).
CONCLUSIONS
Longer duration of lactation is associated with a lower risk of type 2 diabetes and a
favorable glucose metabolic biomarker profile among women with a history of
GDM. The underlying mechanisms and impact on diabetes complications, mor-
bidity, and mortality remain to be determined.
Aswomen undergo changes inmetabolism tomeet the demands of the growing fetus
and to prepare for delivery and lactation (1), they often experience deterioration in
insulin sensitivity during normal pregnancy (2). Although most women maintain
glucose homeostasis by a compensatory increase in insulin secretion (1,3), this
compensatory mechanism is insufficient in some women, resulting in gestational
diabetes mellitus (GDM), which affects ;5–9% of pregnancies in the U.S. (4,5).
Because women with a history of GDM are at higher risk for type 2 diabetes later in
life (6,7), it is critical to identify modifiable determinants of type 2 diabetes risk preven-
tion specific for these high-risk women.
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Breastfeeding has a potential role in
women’s cardiometabolic health (8,9),
including type 2 diabetes prevention
(10–12). In ongoing large-scale pro-
spective cohorts of .150,000 parous
women in the U.S. (13), longer duration
of lactation was associated with lower
risk for type 2 diabetes later in life.
More recent investigations from other
prospective studies in the U.S. and Europe
demonstrated that the protective associ-
ation was also evident among women
with a history of GDM (14–16). In ad-
dition to women with a history of GDM
being at a higher risk for type 2 diabetes
progression later in life (6,7), women
with diabetes during pregnancy experi-
ence breastfeeding challenges in early
postpartum, including delayed onset of
“milk coming in,” also known as lacto-
genesis II (17). Therefore, targeting breast-
feedinghasapreventivepotential, especially
among thesehigh-riskwomenwith a history
of GDM.
In addition to larger-scale prospective
data, previous short-term investigations
have reported the favorable recovery of
insulin sensitivity among women who
breastfeed in the early postpartum pe-
riod (18,19). However, data are lacking
on the association between lactation du-
ration and biomarkers of glucose metab-
olism long-term after the index pregnancy.
We therefore measured fasting plasma
insulin and C-peptide concentrations
among middle-aged women with a his-
tory of GDM. The objective of this study
was to determine the associations of
lifetime lactation duration with inci-
dent type 2 diabetes risk and biomarkers
of glucose metabolism later in life among
women with a history of GDM.
RESEARCH DESIGN AND METHODS
Study Population
The Nurses’ Health Study (NHS) II is an
on-going prospective cohort of 116,671
female registered nurses from the U.S.
aged 25–42 years in 1989. Participants
were monitored biennially using validated
questionnaires on medical history and
lifestyle. NHS II participants were eligi-
ble for inclusion in the current study if
they reported a history of GDM in 1991 or
incident GDM through the biennial ques-
tionnaires up to 2001 or through a 2009
pregnancy questionnaire, which inquired
about physician diagnoses of GDM. In a re-
viewofmedical records among 120women,
94% were confirmed to have a “definite or
probable” diagnosis of GDM (20). In a
random sample of parous women (n 5
100), a high level ofGDMsurveillancewas
documented in this cohort, with 83%
reporting they underwent a glucose chal-
lenge test during pregnancy and 100%
reporting frequent prenatal urine screen-
ing. Participants were excluded if they
reported cancer, cardiovascular disease,
or multiple-birth pregnancy before the
GDM pregnancy or were missing impor-
tant data such as lactation information
and BMI at age 18 years. We therefore
included 4,372 women with a history of
GDM. Between 2012 and 2014, the NHS II
participants who reported a history of
GDM were invited to participate in the
Diabetes &Women’s Health (DWH) Study.
Details of the DWH study protocol have
been published previously (21). Fasting
blood samples were collected from 934
women (21), and the baseline character-
istics of those who provided blood sam-
ples were similar to the entire study
population of women with a history of
GDM. The current biomarker analysis in-
cluded DWH study participants in NHS
II who were free from type 2 diabetes,
definedas hemoglobinA1c (HbA1c),6.5%
(48 mmol/mol) at the follow-up blood
collection and who had data on duration
of lactation and samples assayed for fasting
insulin and C-peptide (n 5 543). The
Brigham and Women’s Hospital Institu-
tional Review Board and the Harvard
T.H. ChanSchool of PublicHealthHuman
Subjects Committee Review Board ap-
proved the study protocol.
Exposure Assessments
Lactationhistorywas obtained fromthree
NHS II follow-up questionnaires. In 1993,
participantswereasked“howmanymonths
in total (all births combined) did youbreast-
feed?”with the following response options:
did not breastfeed,,1, 1–3, 4–6, 7–11, 12–
17, 18–23, 23–35, 36–47, $48 months,
cannot remember. Similar questionnaires
were sent in 1997 and 2003 to update and
overwrite lactation information with the
latest response. Lifetime duration of lac-
tationwas calculated from the sum of the
number of months after each birth that
the participant reported any breastfeed-
ing. Duration of exclusive breastfeeding
was similarly calculated using the re-
ported timing of introduction of formula or
solids after each birth.
Information on other potential risk fac-
tors, including medical, demographic, and
reproductive histories, lifestyle practices,
and body weight, were collected through
NHS II biennial questionnaires. The validity
of these assessments has been docu-
mented previously (22). Parity was de-
finedas thenumberofpregnancies lasting
.6 months and updated through fol-
low-up questionnaires. Age at first birth
was collected through the NHS II bi-
ennial questionnaire in 2007. To reflect
the earliest available lifestyle informa-
tion during reproductive years, lifestyle
data collected in 1991 were used. Di-
etary intake was assessed using a val-
idated semiquantitative food frequency
questionnaire in 1991 (23,24).Diet quality
was assessed using the Alternate Healthy
Eating Index 2010 score, which was de-
veloped to determine scores for foods and
nutrientsmost consistently associatedwith
lower chronic disease risk (25). Physical
activity was ascertained in 1991, and
MET-hours per week was derived (26).
As a surrogate prepregnancy BMI mea-
sure, BMI at age 18 years was calculated
as self-reported weight (kg) at age 18 years
divided by the square of height (m2). The
previous validation study showed self-
reportedweightswere highly correlated
with measured weights (r 5 0.97) (27).
Type 2 Diabetes Ascertainment
The baseline questionnaire and all bi-
ennial follow-up questionnaires asked
participants about the incidence of
physician-diagnosed diabetes. Partic-
ipants who reported such a diagnosis
received a supplementary questionnaire
asking about symptoms, diagnostic tests,
and treatment to confirm the diagnosis.
The validity of the supplementary ques-
tionnaire for type 2 diabetes has been
documented previously (28,29), in which
self-reported diagnosis of diabetes was
confirmedbymedical recordsreviewedby
an endocrinologist blinded to the supple-
mentary questionnaire information for 61of
62 (98%) participants randomly selected in
the NHS.
The diagnosis was confirmed if at least
one of the following was reported ac-
cording to the National Diabetes Data
Group criteria (30): 1) at least one symp-
tom (excessive thirst, polyuria, weight loss,
or hunger) plus fasting glucose$7.8mmol/
L or random glucose $11.1 mmol/L; 2) in
the absence of symptoms, at least two
elevated glucose concentrations on dif-
ferent occasions (fasting glucose .7.8
mmol/L, random glucose $11.1 mmol/L,
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and/or 2-h postload $11.1 mmol/L at
an oral glucose tolerance test); or 3)
treatment with insulin or oral hypogly-
cemic medication. For the cases iden-
tified after 1998, the revised American
Diabetes Association criteria were ap-
plied using the fasting glucose cutoff of
7.0 mmol/L (31).
Biochemical Analysis
Blood sample collection was described
in detail previously (21). Briefly, a phle-
botomy kit and instructions for fasting
blood collection were sent to partici-
pants in 2012–2014. Samples were re-
turned via overnight shipping to a central
laboratory where blood was processed
according to standardized procedures
and stored at 280°C. HbA1c was mea-
sured using a nonporous ion exchange
high-performance liquid chromatograph
assay (Tosoh Automated Analyzer HLC-
723G8; Tosoh Bioscience, Inc., San Fran-
cisco, CA) (interassay coefficient of variation
[CV] ,1.2%). C-peptide concentrations
were measured using C-peptide micro-
ELISA (Quansys Biosciences, Logan, UT)
(interassay CV 10.0% at 3.6 ng/mL and
7.3% at 1.9 ng/mL). Insulin concentra-
tions were measured using the cobas
6000 chemistry analyzer (Roche Diag-
nostics, Indianapolis, IN) (interassay
CV 3.1% at 121.2 pmol/L and 3.1% at
377.9 pmol/L).
Statistical Analysis
Distributions of continuous variables were
assessed for normality, and natural log
transformations of skewed biomarkers
were used in subsequent analyses. De-
scriptive statistics for continuous varia-
bles are summarized as mean 6 SD, and
categorical variables are summarized using
proportions according to lactation dura-
tion categories.
Participants contributed to person-time
from the date of the GDMdiagnosis to the
date of the type 2 diabetes diagnosis,
death, or the end of follow-up, whichever
came first. We used multivariable time-
dependent Cox proportional hazards
models to estimate hazard ratio (HR)
and 95% CI, and the time scale for the
left-truncated survival model was age
(months). Model 1 was age adjusted.
Model 2 was additionally adjusted for
ethnicity (white/nonwhite), family history
of diabetes (yes/no), parity, and age at first
birth (,25, 25–29, 30–34, $35 years).
Model3wasadditionallyadjusted forever
smoking assessed in 1991 (yes/no), diet
qualityassessed in1991 (tertiles), physical
activity in 1991 (tertiles), and prepreg-
nancyBMI (#23,.23–25,.25–27,.27–
30,.30 kg/m2). For age at first birth (1%
missing), missing indicators were gener-
ated to treat missing as a separate cat-
egory. Tests for trend were conducted by
assigning amedian value to each category
and modeling this value as a continuous
variable.General linearmodelswere used
to assess associations of lactation dura-
tion with glucose metabolic biomarkers
among women free of type 2 diabetes at
the follow-up blood draw, defined as
HbA1c ,6.5% (48 mmol/mol). Potential
interactions were tested by adding an in-
teraction term of lactation duration (con-
tinuous) with age (continuous), parity
(continuous), primipara (yes/no), prepreg-
nancy BMI (continuous), and age at index
GDM diagnosis (continuous) with adjust-
ment for covariates included inmodel 2.
For all statistical analyses, two-sided
P , 0.05 was considered to be statisti-
cally significant. All data analyses were
performed using SAS 9.4 software for
UNIX (SAS Institute, Cary, NC).
RESULTS
We documented 873 incident cases of
type 2 diabetes among 4,372 women
with a history of GDM during 87,411
person-yearsof follow-up.Womenwerea
median age 31.8 (95% CI 25.2–40.2) years
at the index GDM diagnosis and 49.8
(39.2–61.5) years at the type 2 diabetes
diagnosis. The age-standardized charac-
teristics of study participants are pre-
sented according to lifetime duration of
lactation in Table 1.
Lactation Duration and Type 2
Diabetes
HRs for developing type 2 diabetes are
presented in Table 2 with models adjust-
ing for other risk factors. A longer lifetime
duration of lactation was associated with
lower risk for type 2 diabetes (Table 2).
When lactation was treated as a continuous
variable per year increase, the associa-
tion remained (HR 0.89 [95% CI 0.83–
0.96]) with themodel 3 adjustment.When
model 3 was additionally adjusted for
marital status (yes/no), the significant
association remained (HR 1.05 [95% CI
0.82–1.34] for up to 6 months, 0.91
[0.71–1.15] for 6–12 months, 0.84 [0.67–
1.06] for 12–24 months, and 0.73 [0.57–
0.93] for .24 months compared with
0 months; P for trend 5 0.004). There
was no statistically significant effect mod-
ification in the association between lac-
tation duration and type 2 diabetes by
age, parity, primipara, prepregnancy BMI,
or age at the index GDM diagnosis.
Similarly, a longer lifetime duration of
exclusive lactation was associated with a
lower risk for type 2 diabetes (Table 3).
Table 1—Characteristics of NHS II participants according to lifetime duration of lactation (N 5 4,372)
0 months .0 to 6 months .6 to 12 months .12 to 24 months .24 months
(n 5 766) (n 5 770) (n 5 871) (n 5 1,082) (n 5 883)
Age at index GDM, years† 32.1 6 4.8 32.5 6 4.8 32.3 6 4.7 32.2 6 4.7 33.2 6 4.8
White 89 88 90 92 94
Family history of diabetes 30 28 25 24 24
Age at first birth, years† 27.3 6 5.1 28.6 6 5.4 28.4 6 5.2 27.5 6 4.8 26.1 6 4.1
Prepregnancy BMI, kg/m2 22.3 6 4.4 21.7 6 3.7 21.2 6 3.1 21.0 6 3.2 21.0 6 2.7
Parity in 1991 1.9 6 0.9 1.8 6 0.8 1.9 6 0.8 2.3 6 0.9 3.0 6 1.1
Ever smoking in 1991 38 37 34 31 29
AHEI in 1991 40.7 6 10.6 42.5 6 10.5 43.7 6 10.1 43.7 6 10.7 43.1 6 10.5
Total activity in 1991, MET-h/week 17.0 6 23.5 16.4 6 19.7 15.9 6 18.2 18.3 6 22.1 17.3 6 21.7
Values are means 6 SD or percentages and are standardized to the age distribution of the study population. AHEI, Alternate Healthy Eating Index.
†Value is not age adjusted.
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Lactation Duration and Biomarkers of
Glucose Metabolism Among Women
Free of Type 2 Diabetes
Multiple regression models were con-
structed to assess whether duration of
lactation was associated with glucose
metabolic biomarkers among women
who provided blood samples in 2012–
2014 (Table 4). At the follow-up blood
collection, women were a median age
of 58.2 (95% CI 51–65) years and 26.3
(95%CI 15.7–34.1) years since theGDM
index pregnancy. Amongwomen freeof
type 2 diabetes at the blood collection, a
longer lactation durationwas significantly
associated with HbA1c, fasting insulin, and
C-peptides (Table 4).
CONCLUSIONS
Among 4,372 women with a history of
GDM during 87,411 person-years of fol-
low-up, longer lifetime lactationduration
was associatedwith a lower risk of type 2
diabetes after adjustment for age at first
birth, ethnicity, family history of diabe-
tes, parity, smoking, diet quality, physical
activity, and prepregnancy BMI. Further,
longer lifetime duration of lactation was
associated with lower concentrations of
HbA1c, fasting insulin, andC-peptide among
middle-aged women without type 2
diabetes.
Our incident type 2 diabetes results
are in general similar to recent reports
from prospective studies in the U.S. and
Europe (14–16). In 155 women with a
history of GDM participating in the Cor-
onary Artery Risk Development in Young
Adults (CARDIA) study (14), lactation
duration had a graded inverse associa-
tion with diabetes incidence. Although
longer duration of lactation was asso-
ciatedwith lower risk for type 2 diabetes
in the NHS and NHS II (13), the associ-
ationwas not statistically significant in a
sensitivity analysis among women
with a history of GDM in the previous
analysis of NHS II using up to 2001 fol-
low-up. Having follow-up data up to
2017 enabled us to perform updated
analyses among women with a history
of GDM in NHS II. In these updated
analysesmonitoring women up to ages in
their early-60s, as opposed to the earlier
report of monitoring up to their mid-40s,
we observed a significant association of
longer lifetimedurationof lactationwith
lower risk for type 2 diabetes among
women with a history of GDM. Since
U.S. women between ages mid-40s and
early-60s experience a sharp increase
in the incidence of type 2 diabetes (32),
this increased power is likely to have
contributed to the detection of a sig-
nificant association of longer lifetime
duration of lactation with lower risk for
type 2 diabetes among women with a
history of GDM.
Previously, the favorable recovery of
postpartumglucosehomeostasishasbeen
documented among women who adopt
breastfeeding behavior in the early post-
partumperiod (18,19,33). Ina clinical study
among 26 women with recent GDM
(14 breastfeeding and 12 nonbreast-
feeding) at 3 months postpartum, the
disposition index, which is the product
of insulin sensitivity times the amount
of insulin secreted in response to blood
glucose concentrations, was higher in
the breastfeeding group (19). However,
whether this early favorable recovery
might have a sustained long-term im-
pact on glucose homeostasis was un-
clear. In a studywith 3-year postpartum
follow-up, women who breastfed for
longer tended to have lower fasting
insulin concentrations, although the as-
sociation did not reach statistical signif-
icance after multiple adjustment (34);
however, these women in their 30s might
recover their glucose homeostasis to some
extent by 3 years postpartum. We have
performed biochemical analysis of fasting
insulin and C-peptide concentrations in
women at a median age of 58 years to
assess the association between earlier
lactation behavior and glucose meta-
bolic biomarkers later in life. We report
the associations of longer lactation du-
ration with lower fasting insulin and
C-peptide concentrations as indicators
Table 2—HR (95% CI) for type 2 diabetes among women with a history of GDM, according to lifetime duration of total lactation
in NHS II (N 5 4,372)
0 months .0 to 6 months .6 to 12 months .12 to 24 months .24 months P for trend
Cases/person-years 178/14,553 155/12,769 151/16,007 205/22,253 184/21,828
Model 1 1 1.01 (0.80–1.28) 0.82 (0.64–1.03) 0.78 (0.62–0.97) 0.67 (0.54–0.84) ,0.0001
Model 2 1 1.04 (0.82–1.32) 0.85 (0.67–1.08) 0.78 (0.62–0.98) 0.64 (0.51–0.82) ,0.0001
Model 3 1 1.05 (0.83–1.34) 0.91 (0.72–1.16) 0.85 (0.67–1.06) 0.73 (0.57–0.93) 0.003
Model 1 adjusted for age.Model 2 additionally adjusted for ethnicity (white/nonwhite), family history of diabetes (yes/no), updated parity, and age at
first birth (,25, 25–29, 30–34,$35 years). Model 3 additionally adjusted for baseline ever smoking (yes/no), baseline diet quality (tertiles), baseline
physical activity (tertiles), and prepregnancy BMI (#23, .23–25, .25–27, .27–30, .30 kg/m2).
Table 3—HR (95% CI) for type 2 diabetes among women with a history of GDM, according to lifetime duration of exclusive
lactation in NHS II (N 5 4,006)
0 months .0 to 6 months .6 to 12 months .12 months P for trend
Cases/person-years 363/30,531 200/19,235 155/18,318 109/14,013
Model 1 1 0.89 (0.74–1.08) 0.73 (0.59–0.89) 0.66 (0.53–0.83) ,0.0001
Model 2 1 0.92 (0.76–1.11) 0.73 (0.60–0.90) 0.64 (0.50–0.82) ,0.0001
Model 3 1 0.96 (0.79–1.16) 0.79 (0.64–0.98) 0.70 (0.54–0.90) 0.002
Model 1 adjusted for age. Model 2 additionally adjusted for ethnicity (white/nonwhite), family history of diabetes (yes/no), updated parity, and age
at first birth (,25, 25–29, 30–34,$35 years). Model 3 additionally adjusted for ever smoking (yes/no), diet quality (tertiles), physical activity (tertiles),
and prepregnancy BMI (#23, .23–25, .25–27, .27–30, .30 kg/m2).
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of insulin action inmiddle-aged women
with a history of GDM and free of type 2
diabetes at follow-up. Although fasting
plasma insulin and C-peptide concen-
trations to some minor extent are influ-
enced by pancreatic insulin secretion
capacity, there is consensus that fasting
plasma insulin and C-peptide predom-
inantly are a measure of insulin resis-
tance in individualswithout severe diabetes
and b-cell defects.
This studyhas several notable strengths.
It is the largest long-term prospective in-
vestigation of lactation, biomarkers of glu-
cose metabolism, and type 2 diabetes
preventionamongwomenwith ahistory
of GDM to date, allowing assessment of
long-term diabetes risk and glucose met-
abolic biomarkers specific to these high-
risk women.
However, the study has several limi-
tations. First, our study participants were
nurses of primarily European ancestry;
therefore, further investigations target-
ing specific populations of more diverse
socioeconomic status are warranted to
develop optimal prevention routes.
Second, our blood samples were shipped
overnight after collection, then pro-
cessed, and stored for 1–3 years at280°C
before biochemical analyses were per-
formed. The process might have intro-
duced molecular degradation, although
stability of these biomarkers after delay
in processing and long-term storage has
been documented previously (35).
Third, wewere not able to obtain valid
measure of fasting plasma concentrations
of glucose in these samples because of
overnightshippingcollectionmethodsused;
therefore, wewere unable to assess HOMA
estimates. However, fasting insulin was
used as a surrogate marker for insulin
resistance because insulin resistance
and hyperinsulinemia rarely exist in iso-
lation in a diabetes-free population (36).
Further, the consistent association be-
tween lactation duration and C-peptide
confirms that its association is unlikely
influenced by exogenous insulin.
Fourth, the observed benefits of lac-
tation may have been confounded by
other healthful behaviors, although we
attempted to account for these con-
founders throughstatistical adjustmentof
regression models.
Fifth, we did not have precise mea-
surements of pregnancy and early post-
partum clinical parameters, including
weight gain and energy expenditure.
Since gestational and postpartum weight
gain (37), energy expenditure during lac-
tation (38), and other pregnancy and
postpartum clinical parameters includ-
ing biochemical measurements and de-
tailed fetus informationmaybe involved
in the mechanism behind the observed
associations, we recommend carefully
designed and controlled future studies
to determine the causality and mecha-
nisms and to examine life stage–specific
questions.
In summary, longer lifetime duration
of lactation is associated with incident
type 2 diabetes and a favorable glucose
metabolic biomarker profile amongmiddle-
aged women with a history of GDM.
Prolonged breastfeeding should be en-
couraged during pregnancy, especially
among women with GDM who are at
increased risk for experiencing breast-
feeding challenges in early postpartum
(17) in addition to being at higher risk for
type 2 diabetes progression later in life
(6,7). It is furthermore important to un-
derstand the underlying mechanisms and
additional potential benefits on diabetes
complications, comorbidity, and mortality.
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Table 4—Least-squares mean (95% CI) biomarker concentrations of glucose metabolic biomarkers according to lifetime duration of
lactation among women free of diabetes (HbA1c <6.5% [48 mmol/mol]) with a history of GDM (n 5 543)
0 months 1–12 months 12–24 months .24 months P for trend
HbA1c, %; mmol/mol
Model 1 5.68 (5.59–5.77);
39 (38–40)
5.64 (5.59–5.70);
38 (38–39)
5.66 (5.61–5.72);
38 (38–39)
5.58 (5.53–5.63);
37 (37–38)
0.03
Model 2 5.69 (5.59–5.78);
39 (38–40)
5.65 (5.59–5.70);
38 (38–39)
5.66 (5.61–5.72);
38 (38–39)
5.57 (5.52–5.63);
37 (37–38)
0.02
Model 3 5.66 (5.56–5.75);
38 (37–39)
5.65 (5.60–5.71);
38 (38–39)
5.66 (5.61–5.72);
38 (38–39)
5.58 (5.53–5.63);
37 (37–38)
0.04
Insulin, pmol/L
Model 1 71.6 (60.5–84.7) 61.3 (55.6–67.6) 54.7 (49.5–60.5) 51.3 (46.8–56.2) 0.0004
Model 2 69.7 (58.8–82.7) 60.6 (54.8–67.0) 54.7 (49.5–60.5) 52.2 (47.3–57.5) 0.005
Model 3 64.7 (54.6–76.8) 61.0 (55.2–67.3) 54.7 (49.5–60.4) 53.1 (48.2–58.5) 0.02
C-peptide, ng/mL
Model 1 4.07 (3.67–4.52) 3.74 (3.52–3.97) 3.48 (3.27–3.70) 3.35 (3.17–3.55) 0.0006
Model 2 4.01 (3.61–4.46) 3.71 (3.49–3.95) 3.48 (3.27–3.70) 3.39 (3.19–3.60) 0.007
Model 3 3.88 (3.49–4.32) 3.73 (3.50–3.96) 3.47 (3.26–3.69) 3.42 (3.22–3.63) 0.02
Model 1 adjusted for age at follow-up blood draw. Model 2 additionally adjusted for ethnicity (white/nonwhite), family history of diabetes (yes/no),
lifetime parity, and age at first birth (,25, 25–29, 30–34,$35 years). Model 3 additionally adjusted for ever smoking (yes/no), diet quality (high/low),
baseline physical activity (high/low), and prepregnancy BMI (#23, .23–25, .25–27, .27–30, .30 kg/m2).
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